Kudva-Patel V, White E, Karnani R, Collins MH, Assa'ad AH "Drug reaction to ceftriaxone in a child with X-linked agammaglobulinemia." South Med J 80 (1987): 274-535. Rohacova H, Hancil J, Hulinska D, Mailer H, Havlik J "Ceftriaxone in the treatment of lyme neuroborreliosis." Call your doctor for medical advice about side effects. "Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers." Precipitation was reversible upon drug discontinuation.Renal precipitation has also been reported during postmarketing experience.Severe and sometimes fatal reactions have been reported in term and premature newborns (younger than 28 days) treated with IV ceftriaxone and calcium-containing IV solutions; a crystalline material (ceftriaxone-calcium precipitate) has been observed in the lungs and kidneys at autopsy. Am Fam Physician 71 (2005): 933-4218. Am J Gastroenterol 86 (1991): 1251-422. The same IV infusion line was used for this drug and calcium-containing solutions in some cases; precipitate was observed in the IV infusion line in some cases. Common side effects may include: mild diarrhea; warmth, tight feeling, or a hard lump where the injection was given; vaginal itching or discharge; rash; or; abnormal liver function tests. Valesova H, Mailer J, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with Lyme arthritis following treatment with ceftriaxone." Clin Pharmacokinet 45 (2006): 493-50121. Lopez AJ, O'Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Roche Laboratories, Nutley, NJ. Risk of forming precipitates was increased in immobilized or dehydrated patients.
Grasberger H, Otto B, Loeschke K "Ceftriaxone-associated nephrolithiasis." Contact Dermatitis 34 (1996): 22640. 4. Hayward CJ, Nafziger AN, Kohlhepp SJ, Bertino JS "Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents." The incidence of warmth, tightness or induration was 17% (3/17) after IM administration of 350 mg/mL and 5% (1/20) after IM administration of 250 mg/mL. This is not a complete list of side effects and others may occur. The most common side effects were Local side effects were increased if water was used as the diluent instead of IM injection has been associated with warmth, tightness, and induration in 17% of patients receiving the 350 mg/mL solution and 5% of patients receiving the 250 mg/mL solution.Bleeding and bruising (due to hypoprothrombinemia) may have been more prevalent in patients with liver or renal dysfunction, malnourished patients, patients with low vitamin K levels, and patients using this drug for a prolonged duration.Shadows on sonograms of the gallbladder (mistaken for Both pseudocholelithiasis (biliary "sludging") and true Hepatitis has also been reported during postmarketing experience.-Frequency not reported: Hepatic dysfunction, cholestasisA case of AGEP has been reported after administration of this drug. Filipe P, Almeida RSLS, Rodrigo FG "Occupational allergic contact dermatitis from cephalosporins." Lewis JD "Liquid sucralfate in the management of aphthous ulcers." N Z Med J 98 (1985): 96930. N Engl J Med 354 (2006): 2794-80131. Clin Infect Dis 24 (1997): 170-826. Nahata MC, Barson WJ "Ceftriaxone: a third-generation cephalosporin." Ceftriaxone may cause reversible biliary pseudolithiasis, notably at higher dosages of the drug (>/=2 g/day); however, the incidence of true lithiasis is <0.1%. Pediat Inf Dis J 17 (1998): 662-329.
Increase In The Number Of Platelets In The Blood Am Fam Physician 64 (2001): 737Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.Some side effects may not be reported. We comply with the HONcode standard for trustworthy health information - Simon N, Dussol B, Sampol E, et al. Ann Pharmacother 25 (1991): 135-615. If experienced, these tend to have a Severe expression 1. J Urol 173 (2005): 577-57836. Valesova M, Mailer H, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with lyme arthritis following treatment with ceftriaxone."
Kudva-Patel V, White E, Karnani R, Collins MH, Assa'ad AH "Drug reaction to ceftriaxone in a child with X-linked agammaglobulinemia." South Med J 80 (1987): 274-535. Rohacova H, Hancil J, Hulinska D, Mailer H, Havlik J "Ceftriaxone in the treatment of lyme neuroborreliosis." Call your doctor for medical advice about side effects. "Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers." Precipitation was reversible upon drug discontinuation.Renal precipitation has also been reported during postmarketing experience.Severe and sometimes fatal reactions have been reported in term and premature newborns (younger than 28 days) treated with IV ceftriaxone and calcium-containing IV solutions; a crystalline material (ceftriaxone-calcium precipitate) has been observed in the lungs and kidneys at autopsy. Am Fam Physician 71 (2005): 933-4218. Am J Gastroenterol 86 (1991): 1251-422. The same IV infusion line was used for this drug and calcium-containing solutions in some cases; precipitate was observed in the IV infusion line in some cases. Common side effects may include: mild diarrhea; warmth, tight feeling, or a hard lump where the injection was given; vaginal itching or discharge; rash; or; abnormal liver function tests. Valesova H, Mailer J, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with Lyme arthritis following treatment with ceftriaxone." Clin Pharmacokinet 45 (2006): 493-50121. Lopez AJ, O'Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Roche Laboratories, Nutley, NJ. Risk of forming precipitates was increased in immobilized or dehydrated patients.
Grasberger H, Otto B, Loeschke K "Ceftriaxone-associated nephrolithiasis." Contact Dermatitis 34 (1996): 22640. 4. Hayward CJ, Nafziger AN, Kohlhepp SJ, Bertino JS "Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents." The incidence of warmth, tightness or induration was 17% (3/17) after IM administration of 350 mg/mL and 5% (1/20) after IM administration of 250 mg/mL. This is not a complete list of side effects and others may occur. The most common side effects were Local side effects were increased if water was used as the diluent instead of IM injection has been associated with warmth, tightness, and induration in 17% of patients receiving the 350 mg/mL solution and 5% of patients receiving the 250 mg/mL solution.Bleeding and bruising (due to hypoprothrombinemia) may have been more prevalent in patients with liver or renal dysfunction, malnourished patients, patients with low vitamin K levels, and patients using this drug for a prolonged duration.Shadows on sonograms of the gallbladder (mistaken for Both pseudocholelithiasis (biliary "sludging") and true Hepatitis has also been reported during postmarketing experience.-Frequency not reported: Hepatic dysfunction, cholestasisA case of AGEP has been reported after administration of this drug. Filipe P, Almeida RSLS, Rodrigo FG "Occupational allergic contact dermatitis from cephalosporins." Lewis JD "Liquid sucralfate in the management of aphthous ulcers." N Z Med J 98 (1985): 96930. N Engl J Med 354 (2006): 2794-80131. Clin Infect Dis 24 (1997): 170-826. Nahata MC, Barson WJ "Ceftriaxone: a third-generation cephalosporin." Ceftriaxone may cause reversible biliary pseudolithiasis, notably at higher dosages of the drug (>/=2 g/day); however, the incidence of true lithiasis is <0.1%. Pediat Inf Dis J 17 (1998): 662-329.
Increase In The Number Of Platelets In The Blood Am Fam Physician 64 (2001): 737Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.Some side effects may not be reported. We comply with the HONcode standard for trustworthy health information - Simon N, Dussol B, Sampol E, et al. Ann Pharmacother 25 (1991): 135-615. If experienced, these tend to have a Severe expression 1. J Urol 173 (2005): 577-57836. Valesova M, Mailer H, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with lyme arthritis following treatment with ceftriaxone."
Kudva-Patel V, White E, Karnani R, Collins MH, Assa'ad AH "Drug reaction to ceftriaxone in a child with X-linked agammaglobulinemia." South Med J 80 (1987): 274-535. Rohacova H, Hancil J, Hulinska D, Mailer H, Havlik J "Ceftriaxone in the treatment of lyme neuroborreliosis." Call your doctor for medical advice about side effects. "Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers." Precipitation was reversible upon drug discontinuation.Renal precipitation has also been reported during postmarketing experience.Severe and sometimes fatal reactions have been reported in term and premature newborns (younger than 28 days) treated with IV ceftriaxone and calcium-containing IV solutions; a crystalline material (ceftriaxone-calcium precipitate) has been observed in the lungs and kidneys at autopsy. Am Fam Physician 71 (2005): 933-4218. Am J Gastroenterol 86 (1991): 1251-422. The same IV infusion line was used for this drug and calcium-containing solutions in some cases; precipitate was observed in the IV infusion line in some cases. Common side effects may include: mild diarrhea; warmth, tight feeling, or a hard lump where the injection was given; vaginal itching or discharge; rash; or; abnormal liver function tests. Valesova H, Mailer J, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with Lyme arthritis following treatment with ceftriaxone." Clin Pharmacokinet 45 (2006): 493-50121. Lopez AJ, O'Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Roche Laboratories, Nutley, NJ. Risk of forming precipitates was increased in immobilized or dehydrated patients.
Grasberger H, Otto B, Loeschke K "Ceftriaxone-associated nephrolithiasis." Contact Dermatitis 34 (1996): 22640. 4. Hayward CJ, Nafziger AN, Kohlhepp SJ, Bertino JS "Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents." The incidence of warmth, tightness or induration was 17% (3/17) after IM administration of 350 mg/mL and 5% (1/20) after IM administration of 250 mg/mL. This is not a complete list of side effects and others may occur. The most common side effects were Local side effects were increased if water was used as the diluent instead of IM injection has been associated with warmth, tightness, and induration in 17% of patients receiving the 350 mg/mL solution and 5% of patients receiving the 250 mg/mL solution.Bleeding and bruising (due to hypoprothrombinemia) may have been more prevalent in patients with liver or renal dysfunction, malnourished patients, patients with low vitamin K levels, and patients using this drug for a prolonged duration.Shadows on sonograms of the gallbladder (mistaken for Both pseudocholelithiasis (biliary "sludging") and true Hepatitis has also been reported during postmarketing experience.-Frequency not reported: Hepatic dysfunction, cholestasisA case of AGEP has been reported after administration of this drug. Filipe P, Almeida RSLS, Rodrigo FG "Occupational allergic contact dermatitis from cephalosporins." Lewis JD "Liquid sucralfate in the management of aphthous ulcers." N Z Med J 98 (1985): 96930. N Engl J Med 354 (2006): 2794-80131. Clin Infect Dis 24 (1997): 170-826. Nahata MC, Barson WJ "Ceftriaxone: a third-generation cephalosporin." Ceftriaxone may cause reversible biliary pseudolithiasis, notably at higher dosages of the drug (>/=2 g/day); however, the incidence of true lithiasis is <0.1%. Pediat Inf Dis J 17 (1998): 662-329.
Increase In The Number Of Platelets In The Blood Am Fam Physician 64 (2001): 737Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.Some side effects may not be reported. We comply with the HONcode standard for trustworthy health information - Simon N, Dussol B, Sampol E, et al. Ann Pharmacother 25 (1991): 135-615. If experienced, these tend to have a Severe expression 1. J Urol 173 (2005): 577-57836. Valesova M, Mailer H, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with lyme arthritis following treatment with ceftriaxone."
Thomas P, Daly S, Misan G, Steele T "Comparison of the efficacy and adverse effect profile of cefotaxime and ceftriaxone in ICU patients with susceptible infections." Lancet 2 (1989): 16523. LOCAL REACTIONS - pain, induration and tenderness was 1% overall. Available for Android and iOS devices. Along with its needed effects, ceftriaxone may cause some unwanted effects. Chemotherapy 27 (1981): 62-925.
Kudva-Patel V, White E, Karnani R, Collins MH, Assa'ad AH "Drug reaction to ceftriaxone in a child with X-linked agammaglobulinemia." South Med J 80 (1987): 274-535. Rohacova H, Hancil J, Hulinska D, Mailer H, Havlik J "Ceftriaxone in the treatment of lyme neuroborreliosis." Call your doctor for medical advice about side effects. "Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers." Precipitation was reversible upon drug discontinuation.Renal precipitation has also been reported during postmarketing experience.Severe and sometimes fatal reactions have been reported in term and premature newborns (younger than 28 days) treated with IV ceftriaxone and calcium-containing IV solutions; a crystalline material (ceftriaxone-calcium precipitate) has been observed in the lungs and kidneys at autopsy. Am Fam Physician 71 (2005): 933-4218. Am J Gastroenterol 86 (1991): 1251-422. The same IV infusion line was used for this drug and calcium-containing solutions in some cases; precipitate was observed in the IV infusion line in some cases. Common side effects may include: mild diarrhea; warmth, tight feeling, or a hard lump where the injection was given; vaginal itching or discharge; rash; or; abnormal liver function tests. Valesova H, Mailer J, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with Lyme arthritis following treatment with ceftriaxone." Clin Pharmacokinet 45 (2006): 493-50121. Lopez AJ, O'Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Roche Laboratories, Nutley, NJ. Risk of forming precipitates was increased in immobilized or dehydrated patients.
Grasberger H, Otto B, Loeschke K "Ceftriaxone-associated nephrolithiasis." Contact Dermatitis 34 (1996): 22640. 4. Hayward CJ, Nafziger AN, Kohlhepp SJ, Bertino JS "Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents." The incidence of warmth, tightness or induration was 17% (3/17) after IM administration of 350 mg/mL and 5% (1/20) after IM administration of 250 mg/mL. This is not a complete list of side effects and others may occur. The most common side effects were Local side effects were increased if water was used as the diluent instead of IM injection has been associated with warmth, tightness, and induration in 17% of patients receiving the 350 mg/mL solution and 5% of patients receiving the 250 mg/mL solution.Bleeding and bruising (due to hypoprothrombinemia) may have been more prevalent in patients with liver or renal dysfunction, malnourished patients, patients with low vitamin K levels, and patients using this drug for a prolonged duration.Shadows on sonograms of the gallbladder (mistaken for Both pseudocholelithiasis (biliary "sludging") and true Hepatitis has also been reported during postmarketing experience.-Frequency not reported: Hepatic dysfunction, cholestasisA case of AGEP has been reported after administration of this drug. Filipe P, Almeida RSLS, Rodrigo FG "Occupational allergic contact dermatitis from cephalosporins." Lewis JD "Liquid sucralfate in the management of aphthous ulcers." N Z Med J 98 (1985): 96930. N Engl J Med 354 (2006): 2794-80131. Clin Infect Dis 24 (1997): 170-826. Nahata MC, Barson WJ "Ceftriaxone: a third-generation cephalosporin." Ceftriaxone may cause reversible biliary pseudolithiasis, notably at higher dosages of the drug (>/=2 g/day); however, the incidence of true lithiasis is <0.1%. Pediat Inf Dis J 17 (1998): 662-329.
Increase In The Number Of Platelets In The Blood Am Fam Physician 64 (2001): 737Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.Some side effects may not be reported. We comply with the HONcode standard for trustworthy health information - Simon N, Dussol B, Sampol E, et al. Ann Pharmacother 25 (1991): 135-615. If experienced, these tend to have a Severe expression 1. J Urol 173 (2005): 577-57836. Valesova M, Mailer H, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with lyme arthritis following treatment with ceftriaxone."
Got something to say?